What are the impacts of the Trump administration’s rescheduling of state-licensed medical cannabis to Schedule III from Schedule I? Could federal rescheduling extend to recreational marijuana later this year? If so, how should companies, firms and operators prepare for a world where significant tax relief and growth opportunities emerge? Would Congress face pressure to consider a federal tax on the budding sector if broader cannabis reform is in the cards? Foley Hoag Partner Jeffrey Schultz joins Bloomberg Intelligence’s Nathan Dean and Holly Froum on this episode of the Votes and Verdicts podcast to discuss these and other questions facing the industry.